全球多发性硬化症市场 – 2029 年行业趋势和预测

全球多发性硬化症市场分析和规模

近年来，多发性硬化症市场预计将在预测期内快速增长。根据美国多发性硬化症协会的数据，多发性硬化症影响了美国约 100 万人和全球 230 万人。每年，被诊断患有多发性硬化症的人数都在增加，因此有必要开发更有效、副作用更少的新药物。发达国家和发展中国家的政府和非政府组织正在加大努力，提高人们对多发性硬化症的认识，并为药物研发投入大量资金。

• Data Bridge Market Research 分析称，2021 年多发性硬化症市场价值为 253.2 亿美元，预计到 2029 年将达到 339.8 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 3.75%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

全球多发性硬化症市场定义

多发性硬化症 (MS) 是一种慢性炎症性免疫介导疾病，会影响脊髓和大脑中的神经细胞，导致脱髓鞘、轴突切断和神经退化。注射、口服和输注药物、肌肉松弛剂、抗抑郁药和物理疗法是一些最广泛使用的治疗方法。干扰素-β 和醋酸格拉替雷是皮下或肌肉注射的注射疗法；口服药物包括特立氟胺、富马酸二甲酯和克拉屈滨；静脉输注治疗包括奥瑞珠单抗、阿仑单抗和那他珠单抗。

报告范围和市场细分

多发性硬化症市场动态

驱动程序

• 多发性硬化症患病率不断上升

多发性硬化症患病率的上升是多发性硬化症市场增长的主要驱动力。复发缓解型多发性硬化症 (RRMS)、原发进展型多发性硬化症 (PPMS)、继发进展型多发性硬化症 (SPMS) 和进展复发型多发性硬化症 (PRMS) 是多发性硬化症的类型，其高患病率将影响预测期内的市场动态。  

• 增加医疗基础设施投资

影响多发性硬化症市场增长率的另一个重要因素是医疗保健支出的增加，这有助于改善其基础设施。

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the multiple sclerosis market. Additionally, high disposable income and increase in the development of innovative monoclonal antibodies, immunosuppressants, immunomodulators and interferons will result in the expansion of multiple sclerosis market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the multiple sclerosis market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the multiple sclerosis market growth during the forecast period.

Restraints/Challenges Global Multiple Sclerosis Market

On the other hand, the high cost associated with the treatment of multiple sclerosis will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the multiple sclerosis market. Additionally, a decline in clinical visits due to COVID0-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This multiple sclerosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the multiple sclerosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Multiple sclerosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Multiple Sclerosis Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of multiple sclerosis in recent months.

Recent Development

• In August 2020, Novartis had announced the launch of Kesimpta (ofatumumab) will U.S. Food and Drug Administration (FDA) approval. It is the first and only self-administered, targeted B-cell therapy for the people suffering from relapsing multiple sclerosis. Kesimpta combines potent efficacy with an acceptable safety profile and can be self-administered at home, filling a critical gap in the treatment of replasing forms of multiple sclerosis (RMS).

Global Multiple Sclerosis Market Scope

The multiple sclerosis market is segmented on the basis of type, drug class, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Clinically isolated syndrome (CIS)
• Relapse-remitting MS (RRMS)
• Primary progressive MS (PPMS)
• Secondary progressive MS (SPMS)

On the basis of type, the multiple sclerosis market is segmented into clinically isolated syndrome (CIS), relapse-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS).

Treatment

• Medications
• Stem Cell Therapy
• Physical Therapy
• Plasma Exchange
• Others

On the basis of treatment, the global multiple sclerosis market is segmented into medication, stem cell therapy, physical therapy, plasma exchange and others. Medication segment is further segmented into injectable therapies, oral medications and intravenous infusion treatments. Injectable therapies are sub-segmented into interferon-beta and glatiramer acetate. Oral medications are sub-segmented into dimethyl fumarate, teriflunomide, and cladribine. Intravenous infusion treatments are sub-segmented into ocrelizumab, natalizumab, and alemtuzumab.

Drug Class

• Immunomodulators
• Immunosuppressants
• Interferons
• Others

On the basis of drug class, the global multiple sclerosis market is segmented into immunomodulators, immunosuppressants, interferons and others.

Diagnosis

• Magnetic Resonance Imaging (MRI)
• Simple Electrical Stimulation Tests
• Lumbar Puncture
• Others

On the basis of diagnosis, the global multiple sclerosis market is segmented into magnetic resonance imaging (MRI), simple electrical stimulation tests, lumbar puncture and others.

Route of Administration

• Oral
• Parenteral
• Others

The route of administration segment for the multiple sclerosis market is segmented into oral, parenteral and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the multiple sclerosis market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the multiple sclerosis market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Multiple Sclerosis Market Regional Analysis/Insights

The Multiple sclerosis market is analysed and market size insights and trends are provided by country, type, treatment, drug class, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Multiple sclerosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the multiple sclerosis market because of the growing prevalence of multiple sclerosis in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to number of population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Multiple Sclerosis Market Share Analysis

多发性硬化症市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对多发性硬化症市场的关注有关。

多发性硬化症市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（耶路撒冷）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 拜耳公司（德国）
• 礼来公司 (美国)
• 默克公司（美国）
• 艾尔建（爱尔兰）
• 阿斯利康（英国）
• AbbVie Inc.（美国）
• 强生私人有限公司（美国）
• Cipla Inc.（美国）  
• 雅培（美国）
• 默克集团（德国）
• Actelion Pharmaceuticals Ltd（瑞士）
• Opexa Therapeutics, Inc.（美国）
• 拜耳公司（德国）

SKU-53151